Company Overview of Sandoz International GmbH
Sandoz International GmbH engages in developing, manufacturing, and marketing generic pharmaceutical products. The company offers oral solids, gels, patch technologies, inhalers, anti-infective medicines, antibiotics, cardiovascular medicines, treatments for central nervous system disorders, gastrointestinal medicines, and oncology and respiratory therapies; medications for blood and blood forming organ disorders; and injectables, including liquid vials, lyophilized vials, powder for oral suspensions, and pre-filled syringes. It also offers biopharmaceuticals, such as biosimilars; oncology injectables; pharmaceutical intermediates, active pharmaceutical ingredients, and finished dosage forms...
Key Executives for Sandoz International GmbH
Chairman of the Executive Board and Head of Anti-Infectives
Head of North American Operations and President of Sandoz US
Head of Legal and General Counsel
Compensation as of Fiscal Year 2014.
Sandoz International GmbH Key Developments
Sandoz Announces US Market Introduction of Tobramycin Inhalation Solution, USP, Generic Version of TOBI
Jul 14 14
Sandoz announced the US market introduction of tobramycin inhalation solution, USP, an authorized generic version of TOBI®, currently marketed by Novartis Pharmaceuticals Corporation 1. Tobramycin inhalation solution, USP is indicated for the management of cystic fibrosis patients whose lungs contain bacteria called P. aeruginosa. Cystic fibrosis is a life-threatening genetic disease that primarily affects the lungs and digestive system. An estimated 30,000 children and adults in the United States (70,000 worldwide) have cystic fibrosis2. Sandoz is marketing tobramycin inhalation solution, USP in 300 mg/5 mL single-dose ampules, the same size and strength that is currently marketed by the brand.
Sandoz Launches Authorized Generic Version of Diovan in US
Jul 8 14
Sandoz announced the US introduction of an authorized generic version of Diovan (valsartan) tablets for the treatment of high blood pressure (HBP). This launch follows the Sandoz US introduction of an authorized generic version of Diovan HCT (valsartan and hydrochlorothiazide) in 2012. Both Diovan and Diovan HCT are marketed in the US by Novartis Pharmaceuticals Corporation (NPC) and are indicated for the treatment of HBP. The most common side effects seen with valsartan in people with high blood pressure are headache, dizziness, flu symptoms, tiredness, and stomach (abdominal) pain. The most common side effects of valsartan seen in people with heart failure are dizziness, low blood pressure, diarrhea, joint and back pain, tiredness, and high blood potassium.
Sandoz Launches Three New Products in Japan, Including Authorized Generics of Valsartan and Zoledronic Acid
Jun 20 14
Sandoz announced the launch in Japan of three new products, including valsartan, a generic version of Novartis’ Diovan® Tablets, zoledronic acid, a generic version of Novartis’ Zometa® for i.v. infusion 4mg/5mL and Losarhyd (losartan potassium/hydrochlorothiazide), a generic version of MSD’s Preminent® Tablets LD. Valsartan and Losarhyd are indicated for the treatment of hypertension. Zoledronic Acid is indicated for the treatment of hypercalcemia of malignancy.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|